Gregory M. Weinhoff - 10 Sep 2024 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Signature
/s/ Gregory M. Weinhoff
Issuer symbol
CNTA
Transactions as of
10 Sep 2024
Net transactions value
-$334,800
Form type
4
Filing time
12 Sep 2024, 20:01:41 UTC
Previous filing
09 Sep 2024
Next filing
27 Sep 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Options Exercise $175,200 +30,000 +13% $5.84 253,369 10 Sep 2024 Direct F1
transaction CNTA Ordinary Shares Sale $510,000 -30,000 -12% $17.00 223,369 10 Sep 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTA Share Option (right to buy) Options Exercise $0 -30,000 -4.9% $0.000000 584,321 10 Sep 2024 Ordinary Shares 30,000 $5.84 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2024.
F3 25% of the shares subject to such option shall vest and become exercisable on March 1, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.